(2) In 428 adenocarcinoma samples approved by pathologic diagnosis, there were 262 (61.2%) lesions of EGFR mutation, 14 (3.3%) lesions of KRAS mutation, 1 (0.2%) lesion of Braf mutation, 9 (2.1%) lesions of EML4‐ALK gene fusion and 2 (0.5%) lesions of ROS1 fusion. This evidence concerns the gene KRAS and adenocarcinoma.